By connecting every link in the development chain, we create a coordinated path from early development to clinical studies, with experts working toward the same goal: getting your program ready for the clinic efficiently and confidently.
From Strategy to Execution
For our clients, LINK Medical serves as a partner that understands the entire development chain, not just the individual parts.
Our experts support the design and interpretation of toxicology and DMPK programs, CMC strategy and documentation, regulatory strategy, planning and submissions, and the execution of clinical studies through our CTU. Working closely with the project team, Contract Development and Manufacturing Organizations (CDMOs) for drug substance and drug product manufacturing, and nonclinical Contract Research Organizations (CROs), we help align activities across functions, create realistic development plans, and establish an efficient path to First-in-Human studies.
Accelerating the Chain to the Clinic
Today’s development programs face increasing scientific, regulatory, and operational complexity. Navigating this complexity requires more than expertise within individual disciplines. It also requires alignment, collaboration, and a clear strategy across the entire development chain.
That’s where LINK Medical adds value.
We help clients link nonclinical development, CMC, regulatory strategy, and clinical execution into one coherent plan, turning complexity into progress and helping promising therapies reach the clinic faster.
From the first nonclinical study to the first dose in humans and beyond, LINK Medical provides the expertise, collaboration, and strategic perspective needed to move your drug development program forward with confidence.
Anita Annas – Principal Consultant Toxicology
Petri Vainio – Chief Scientific Officer CTU
Sanna Tikka – Site Manager CTU
Ulrika Andersson– Sr Director Drug Development
Bengt Hedin – Principal Consultant Pharmaceutical Development & CMC
Elsa Lilienberg – Principal Consultant Clinical Pharmacology & DMPK
David Dahlgren – Principal Consultant Clinical Pharmacology & DMPK
Ulrika Bergström – Senior Consultant Toxicology
Linda Nord – Principal Consultant Regulatory Affairs
